HR Portal

ECLIPSE trial

Concerns domain scores worsened with Exjade DT but stayed consistent with Jadenu FCT from start to end of trial

ECLIPSE trial

Never through about stopping medication.

ECLIPSE trial

Patients reported better adherence, greater satisfaction, and fewer concerns with Jadenu FCT

Dear Dr., Jadenu provides a simplified formulation of deferasirox.

ECLIPSE trial

Safety of Jadenu FCT comparable with Exjade DT.

Dear Dr., Jadenu adverse drug reactions are generally mild to moderate and can be managed without discontinuation.

Good safety profile for pediatric and adult patients.

Dear Dr., There have been post marketing reports of the following adverse drug reaction in patients treated with deferasirox.

Long-term safety profile for adults and pediatric patients.

Dear Dr., Optimize dosing with Jadenu in TDT patients.

Dear Dr., Jadenu can provide significant, sustained reductions of cardiac and hepatic iron overload.

-2YEAR IMPROVEMENT IN mT2*3

Dear Dr., Jadenu can provide significant, sustained reductions of cardiac and hepatic iron overload.

LIC REDUCTION THROUGH 5 YEARS

Dear Dr., Jadenu can provide significant, sustained reductions of cardiac and hepatic iron overload.

3-YEAR LIC REDUCTION

Dear Dr., Jadenu can effectively reduce cardiac and hepatic iron in cases of high or low iron burden.

Dear Dr., For TDT patients with chronic iron overload. Jadenu can provide significant, sustained reductions in serum ferritin.

Jadenu has the same proven efficacy of deferasirox in a once-daily FCT.

Dear Dr., The FCT formulation of deferasirox may enhance serum ferritin reduction vs DT

A greater reduction in serum ferritin was predicted with deferasirox FCT VS DT over 1 year of therapy and was attributed to improve adherence

Dear Dr., Real-world evidence shows switching to Jadenu improves adherence.

Significantly more patients achieved optimal levels of adherence and persistence to Deferasirox after switching from DT to FCT.